GENB GENERATE BIOMEDICINES INC revenue, earnings and financials
For the quarter ended June 30, 2026, GENERATE BIOMEDICINES INC reported revenue of $6.31M (down 37.7% from a year earlier), net income of −$67.3M and diluted EPS of −$0.52.
GENB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $6.31M (down 37.7% year over year), net income −$67.3M, EPS −$0.52
- Quarter ended Mar 31, 2026: revenue $7.22M (down 18.1% year over year), net income −$61.4M, EPS −$1.07
- Quarter ended Jun 30, 2025: revenue $10.1M, net income −$52.4M, EPS −$1.94
- Quarter ended Mar 31, 2025: revenue $8.82M, net income −$41.7M, EPS −$1.62
GENB balance sheet
- Jun 30, 2026: cash $135M, total assets $562M, total liabilities $106M, shareholders' equity $456M
- Mar 31, 2026: cash $161M, total assets $626M, total liabilities $111M, shareholders' equity $515M
- Dec 31, 2025: cash $122M, total assets $330M, total liabilities $142M, shareholders' equity −$616M